SUBSCRIBE
SUBSCRIBE

Michael Gibney

Michael Gibney is a freelance writer with more than a decade covering the biotech, pharmaceutical and healthcare industries. Most recently he served as senior writer and editor at PharmaVoice.

Pictured: Eli Lilly Campus in San Diego
Metabolic disorders
Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate
Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.
June 1, 2026
 · 
2 min read
 · 
Michael Gibney